The whole world was excited when the news about COVID-19 vaccine developed by Pfizer last week was delivered. This is because Pfizer announced an interim result that the mRNA vaccine, which is being developed jointly with BioNTech in Germany, showed more than 90% prevention effect.

The company recruited about 44,000 participants in clinical trials from five countries, including the United States, and divided them into two groups, receiving COVID-19 vaccine on one side and a placebo on the other. Among them, as a result of analyzing 94 people who were diagnosed with COVID-19, participants who received the vaccine twice had an infection rate of less than 10%, and no serious side effects were observed.